Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 2/2023

11.01.2023 | Review Article

Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin

verfasst von: Sophia Ly, Dmitry Nedosekin, Henry K. Wong

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Biologic therapies targeting B-cells are emerging as an effective strategy to treat a variety of immune-mediated diseases. One of the most studied B-cell-targeted therapies is rituximab, an anti-CD20 monoclonal antibody that exemplifies B-cell depletion therapy and has served as the prototype for other anti-CD20 monoclonal antibodies and the development of biosimilars. While there are multiple studies on the use of rituximab in dermatology, a comprehensive review of rituximab therapy in autoimmune skin conditions is lacking. In this literature review, we summarize indications, treatment efficacy, and safety of rituximab among common autoimmune diseases of the skin: pemphigus vulgaris, cutaneous lupus erythematous, dermatomyositis, systemic sclerosis, thyroid dermopathy, autoimmune pemphigoid diseases, and cutaneous vasculitis diseases. Existing data on rituximab support the approach of rituximab, biosimilars, and newer B-cell-targeting therapies in immune-mediated cutaneous diseases. Overall, rituximab, which targets CD20, provides an effective alternative or concomitant option to traditional immunosuppressants in the management of various autoimmune diseases of the skin. Further studies are necessary to expand the understanding and possible utility of B-cell-targeted therapies among autoimmune skin diseases.
Literatur
1.
Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021;20(3):179–99.PubMedCrossRef
2.
Bonasia CG, Abdulahad WH, Rutgers A, Heeringa P, Bos NA. B cell activation and escape of tolerance checkpoints: recent insights from studying autoreactive B cells. Cells. 2021;10:1190.PubMedPubMedCentralCrossRef
3.
4.
Sarsour K, Beckley-Kartey S, Melega S, Odueyungbo A, Kirchner P, Khalife N, et al. Rituximab utilization for approved and off-label nononcology indications and patients’ experiences with the patient alert card. Pharmacol Res Perspect. 2020;8: e00555.PubMedPubMedCentralCrossRef
5.
6.
Cobb P, Niederwieser D, Cohen S, Hamm C, Burmester G, Seo N, et al. A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar. Immunotherapy. 2022;14:727–40.PubMedCrossRef
7.
8.
Sharman JP, Liberati AM, Ishizawa K, Khan T, Robbins J, Alcasid A, et al. A randomized, double-blind, efficacy and safety study of PF-05280586 (a rituximab biosimilar) compared with rituximab reference product (MabThera®) in subjects with previously untreated cd20-positive, low-tumor-burden follicular lymphoma (LTB-FL). BioDrugs. 2020;34:171–81.PubMedCrossRef
9.
10.
Furie R, Petri M, Zamani O. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2022;63:3918–30.CrossRef
11.
Frampton JE. Rituximab: a review in pemphigus vulgaris. Am J Clin Dermatol. 2020;21(1):149–56.PubMedCrossRef
12.
Ahmed AR, Carrozzo M, Caux F. Monopathogenic vs multipathogenic explanations of pemphigus pathophysiology. Exp Dermatol. 2016;25(11):839–46.PubMedCrossRef
13.
Melchionda V, Harman KE. Pemphigus vulgaris and pemphigus foliaceus: an overview of the clinical presentation, investigations and management. Clin Exp Dermatol. 2019;44:740–6.PubMedCrossRef
14.
Daneshvar E, Tavakolpour S, Mahmoudi H, Daneshpazhooh M, Teimourpour A, Aslani S, et al. Elevated serum level of B-cell activating factor (BAFF) after rituximab therapy in pemphigus vulgaris patients suggests a possible therapeutic efficacy of B-cell depletion therapies combined with anti-BAFF agents. Int J Dermatol. 2022. https://​doi.​org/​10.​1111/​ijd.​16363.CrossRefPubMed
15.
Tavakolpour S, Mahmoudi H, Karami F, Elikaei Behjati S, Balighi K, Abbasi M, et al. Investigating expression pattern of eight immune-related genes in pemphigus patients compared with the healthy controls and after rituximab therapy: potential roles of CTLA4 and FCGR3A genes expression in outcomes of rituximab therapy. Dermatol Ther. 2020;33: e14380.PubMedCrossRef
16.
Joly P, Maho-Vaillant M, Prost-Squarcioni C. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389:2031–40.PubMedCrossRef
17.
Werth VP, Joly P, Mimouni D, Maverakis E, Caux F, Lehane P, et al. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N Engl J Med. 2021;384:2295–305.PubMedCrossRef
18.
Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol. 2022;47(5):785–8.CrossRef
19.
Tavakolpour S, Mahmoudi H, Balighi K, Abedini R, Daneshpazhooh M. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review. Int Immunopharmacol. 2018;54:131–8.PubMedCrossRef
20.
Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772–9.PubMedCrossRef
21.
Joly P, Mouquet H, Roujeau J-C. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:545–52.PubMedCrossRef
22.
Horváth B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus. Br J Dermatol. 2012;166:405–12.PubMedCrossRef
23.
Balighi K, Daneshpazhooh M, Khezri S, Mahdavi-nia M, Hajiseyed-javadi M, Chams-Davatchi C. Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial. Int J Dermatol. 2013;52:862–7.PubMedCrossRef
24.
Loi C, Magnano M, Ravaioli GM, Sacchelli L, Patrizi A, Bardazzi F. Rituximab therapy in pemphigus: a long-term follow-up. Dermatol Ther. 2019;32(1): e12763.PubMedCrossRef
25.
Wang H-H, Liu C-W, Li Y-C, Huang Y-C. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95:928–32.PubMedCrossRef
26.
Kanwar AJ, Vinay K, Sawatkar GU. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Br J Dermatol. 2014;170:1341–9.PubMedCrossRef
27.
Iraji F, Danesh F, Faghihi G. Comparison between the efficacy of intralesional rituximab versus intralesional triamcinolone in the treatment refractory Pemphigus Vulgaris lesions: a randomized clinical trial. Int Immunopharmacol. 2019;73:94–7.PubMedCrossRef
28.
Kushner CJ, Wang S, Tovanabutra N, Tsai DE, Werth VP, Payne AS. Factors associated with complete remission after rituximab therapy for pemphigus. JAMA Dermatol. 2019;155:1404–9.PubMedPubMedCentralCrossRef
29.
Huang A, Madan RK, Levitt J. Future therapies for pemphigus vulgaris: rituximab and beyond. J Am Acad Dermatol. 2016;74:746–53.PubMedCrossRef
30.
Klufas DM, Amerson E, Twu O, Clark L, Shinkai K. Refractory pemphigus vulgaris successfully treated with ofatumumab. JAAD Case Rep. 2020;6:734–6.PubMedPubMedCentralCrossRef
31.
Rapp M, Pentland A, Richardson C. Successful treatment of pemphigus vulgaris with ofatumumab. J Drugs Dermatol. 2018;17(12):1338–9.PubMed
32.
33.
Ellebrecht CT, Choi EJ, Allman DM. Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgaris. JAMA Dermatol. 2014;150:1331–5.PubMedPubMedCentralCrossRef
34.
Ruan J, Zhang X, Zheng M. Belimumab for the treatment of pemphigus. Dermatol Ther. 2022;35(8): e15621.PubMedCrossRef
35.
Hall RP, Streilein RD, Hannah DL. Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. J Invest Dermatol. 2013;133:2786–8.PubMedCrossRef
36.
Thomas RM, Colon A, Motaparthi K. Rituximab in autoimmune pemphigoid diseases: indications, optimized regimens, and practice gaps. Clin Dermatol. 2020;38:384–96.PubMedCrossRef
37.
Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges. 2011;9(10):844–57.PubMed
38.
Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 2: diagnosis and therapy. JDDG J der Dtsch Dermatologischen Gesellschaft. 2011;9:927–47.
39.
Ronaghy A, Streilein RD, Hall RP. Rituximab decreases without preference all subclasses of IgG anti-BP180 autoantibodies in refractory bullous pemphigoid (BP). J Dermatol Sci. 2014;74(1):93–4.PubMedCrossRef
40.
Tsai Y-J, Cho Y-T, Chu C-Y. Clinical effectiveness and safety of initial combination therapy with corticosteroids and rituximab in bullous pemphigoid: a retrospective cohort study. Am J Clin Dermatol. 2022;23:571–85.PubMedCrossRef
41.
Cho YT, Chu CY, Wang LF. First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid. Br J Dermatol. 2015;173:302–4.PubMedCrossRef
42.
Polansky M, Eisenstadt R, DeGrazia T, Zhao X, Liu Y, Feldman R. Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients. J Am Acad Dermatol. 2019;81:179–86.PubMedCrossRef
43.
Ahmed AR, Shetty S, Kaveri S, Spigelman ZS. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: a retrospective study with a 6-year follow-up. J Am Acad Dermatol. 2016;74:700-8.e3.PubMedCrossRef
44.
Yoo DS, Lee JH, Kim S-C, Kim JH. Mortality and clinical response of patients with bullous pemphigoid treated with rituximab. Br J Dermatol. 2021;185:210–2.PubMedCrossRef
45.
Lamberts A, Euverman HI, Terra JB, Jonkman MF, Horváth B. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases. Front Immunol. 2018;9:248–248.PubMedPubMedCentralCrossRef
46.
Silva N, Costa A, Salvador F, Serradeiro E. Bullous pemphigoid successfully treated with rituximab. Acta Med Port. 2022;30:243–6.CrossRef
47.
Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2022;65:552–8.CrossRef
48.
Wang T-S, Tsai T-F. Remission of bullous pemphigoid after rituximab treatment in a psoriasis patient on regular low-dose methotrexate. Acta Derm Venereol. 2022;94:108–9.CrossRef
49.
50.
Maley A, Warren M, Haberman I, Swerlick R, Kharod-Dholakia B, Feldman R. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). J Am Acad Dermatol. 2013;74:835–40.CrossRef
51.
Shetty S, Ahmed AR. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol. 2015;68:499–506.CrossRef
52.
Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol. 147:843–849.
53.
Dastmalchi DA, Moslemkhani S, Bayat M, et al. The efficacy of rituximab in patients with mucous membrane pemphigoid. J Dermatolog Treat. 2022;33(2):1084–90.CrossRef
54.
Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology. 2010;117:861–9.PubMedCrossRef
55.
Li Z, Jing K, Li S, Feng S. Antigen recognition in the pathogenesis of immunoglobulin A-related autoimmune bullous diseases. Postep Dermatol Alergol. 2018;35:338–43.CrossRef
56.
Matsumoto T, Nakamura S, Ishii N. Erythrodermic linear IgA/IgG bullous dermatosis. Eur J Dermatol. 2019;29:220–1.PubMed
57.
Sakaguchi M, Bito T, Oda Y. Three cases of linear IgA/IgG bullous dermatosis showing IgA and IgG reactivity with multiple antigens, particularly laminin-332. JAMA Dermatol. 2013;149:1308–13.PubMedCrossRef
58.
İslamoĝlu ZGK, Akyürek FT. A case of recalcitrant linear IgA bullous dermatosis: successfully treated with rituximab. Dermatol Ther. 2019;32(3): e12911.
59.
60.
Nedosekin D. Immunologic overlap in a case of linear IgG/IgA bullous dermatosis responsive to rituximab: a case report and discussion. JAAD case reports. 2021;9:57–60.PubMedPubMedCentralCrossRef
61.
Iwata H, Vorobyev A, Koga H. Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients. Orphanet J Rare Dis. 2018;13(1):153.PubMedPubMedCentralCrossRef
62.
Yang A, Kim M, Craig P, Murrell DF. A case report of the use of rituximab and the epidermolysis bullosa disease activity scoring index (EBDASI) in a patient with epidermolysis bullosa acquisita with extensive esophageal involvement. Acta Dermatovenerol Croat. 2018;26(4):325–8.PubMed
63.
Bevans SL, Sami N. The use of rituximab in treatment of epidermolysis bullosa acquisita: three new cases and a review of the literature. Dermatol Ther. 2018;31(6): e12726.PubMedCrossRef
64.
Oktem A, Akay BN, Boyvat A. Long-term results of rituximab-intravenous immunoglobulin combination therapy in patients with epidermolysis bullosa acquisita resistant to conventional therapy. J Dermatolog Treat. 2016;28:50–4.PubMedCrossRef
65.
McKinley SK, Huang JT, Tan J, Kroshinsky D, Gellis S. A case of recalcitrant epidermolysis bullosa acquisita responsive to rituximab therapy. Pediatr Dermatol. 2014;31:241–4.PubMedCrossRef
66.
Saha M, Cutler T, Bhogal B, Black MM, Groves RW. Refractory epidermolysis bullosa acquisita: successful treatment with rituximab. Clin Exp Dermatol. 2009;34(8):e979–80.PubMedCrossRef
67.
Lipozenčić J, Ljubojevic S, Bukvić-Mokos Z. Pemphigoid gestationis. Clin Dermatol. 2012;30:51–5.PubMedCrossRef
68.
Cianchini G, Masini C, Lupi F, Corona R, Pità O, Puddu P. Severe persistent pemphigoid gestationis: long-term remission with rituximab. Br J Dermatol. 2007;157:388–9.PubMedCrossRef
69.
Tourte M, Brunet-Possenti F, Mignot S, Gavard L, Descamps V. Pemphigoid gestationis: a successful preventive treatment by rituximab. J Eur Acad Dermatol Venereol. 2017;31(4):e206–7.PubMedCrossRef
70.
Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117:1499–506.PubMedCrossRef
71.
Kasi PM, Tawbi HA, Oddis CV, Kulkarni HS. Clinical review: serious adverse events associated with the use of rituximab—a critical care perspective. Crit Care. 2012;16(4):231.PubMedPubMedCentralCrossRef
72.
73.
Silva-Fernández L, Loza E, Martínez-Taboada VM. Biological therapy for systemic vasculitis: a systematic review. Semin Arthritis Rheum. 2014;43:542–57.PubMedCrossRef
74.
Taha R, El-Haddad H, Almuallim A, Alshaiki F, Obaid E, Almoallim H. Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schönlein purpura, ankylosing spondylitis, and Raynaud’s phenomenon. Open Access Rheumatol. 2017;9:201–14.PubMedPubMedCentralCrossRef
75.
Yates M, Watts R. ANCA-associated vasculitis. Clin Med. 2017;17:60–4.CrossRef
76.
Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis. 2009;68:1827–32.PubMedCrossRef
77.
78.
Jones RB, Tervaert JWC, Hauser T. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211–20.PubMedCrossRef
79.
Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, et al. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial. JAMA. 2021;325:2178–87.PubMedCrossRef
80.
Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771–80.PubMedCrossRef
81.
Charles P, Terrier B, Perrodeau É, Cohen P, Faguer S, Huart A, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77:1143–9.PubMedCrossRef
82.
Wink F, Houtman PM, ThA J. Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature. Clin Rheumatol. 2010;30:293–300.PubMedCrossRef
83.
Silva F, Pinto C, Barbosa A, Borges T, Dias C, Almeida J. New insights in cryoglobulinemic vasculitis. J Autoimmun. 2019;105: 102313.PubMedCrossRef
84.
Pietrogrande M, Vita S, Zignego AL. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev. 2011;10:444–54.PubMedCrossRef
85.
Saadoun D, Resche-Rigon M, Sene D, Perard L, Karras A, Cacoub P. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis. 2008;67(10):1431–6.PubMedCrossRef
86.
Ferri C, Cacoub P, Mazzaro C. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: Results of multicenter cohort study and review of the literature. Autoimmun Rev. 2010;11:48–55.CrossRef
87.
Vita S, Quartuccio L, Isola M. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2015;64:843–53.CrossRef
88.
Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2013;64:835–42.CrossRef
89.
Colantuono S, Mitrevski M, Yang B. Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis. Clin Rheumatol. 2021;36:617–23.CrossRef
90.
Visentini M, Ludovisi S, Petrarca A. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev. 2016;10:714–9.CrossRef
91.
Harel S, Mohr M, Jahn I. Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases. Br J Haematol. 2015;168(5):671–8.PubMedCrossRef
92.
Gragnani L, Visentini M, Fognani E. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 2016;64:1473–82.PubMedCrossRef
93.
Ozen S, Marks SD, Brogan P. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatol (Oxford). 2019;58:1607–16.CrossRef
94.
Maritati F, Fenoglio R, Pillebout E, Emmi G, Urban ML, Rocco R, et al. Brief report: rituximab for the treatment of adult-onset iga vasculitis (Henoch-Schönlein). Arthritis Rheumatol (Hoboken, NJ). 2018;70:109–14.CrossRef
95.
Fenoglio R, Sciascia S, Naretto C, De Simone E, Del Vecchio G, Ferro M, et al. Rituximab in severe immunoglobulin-A vasculitis (Henoch-Schönlein) with aggressive nephritis. Clin Exp Rheumatol. 2020;38(Suppl 1):195–200.PubMed
96.
Crayne CB, Eloseily E, Mannion ML, Azerf SP, Weiser P, Beukelman T, et al. Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature. Pediatr Rheumatol Online J. 2018;16:71.PubMedPubMedCentralCrossRef
97.
Hernández-Rodríguez J, Carbonell C, Mirón-Canelo J-A, Diez-Ruiz S, Marcos M, Chamorro AJ. Rituximab treatment for IgA vasculitis: a systematic review. Autoimmun Rev. 2020;19(4): 102490.PubMedCrossRef
98.
DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol. 2020;82:267–81.PubMedCrossRef
99.
Sasaki H, Takamura A, Kawahata K, Takashima T, Imai K, Morio T, et al. Peripheral blood lymphocyte subset repertoires are biased and reflect clinical features in patients with dermatomyositis. Scand J Rheumatol. 2019;48:225–9.PubMedCrossRef
100.
Wang W-M, Guo L, Jin H-Z. Role of B cells in immune-mediated dermatoses. Mol Immunol. 2020;126:95–100.PubMedCrossRef
101.
Li W, Tian X, Lu X, Peng Q, Shu X, Yang H, et al. Significant decrease in peripheral regulatory B cells is an immunopathogenic feature of dermatomyositis. Sci Rep. 2016;6:1–11.
102.
Waldman R, DeWane ME, Lu J. Dermatomyositis: diagnosis and treatment. J Am Acad Dermatol. 2020;82:283–96.PubMedCrossRef
103.
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314–24.PubMedPubMedCentralCrossRef
104.
Sultan SM, Allen E, Oddis CV, Kiely P, Cooper RG, Lundberg IE, et al. Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum. 2008;58:3593–9.PubMedCrossRef
105.
106.
Aggarwal R, Bandos A, Reed AM. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol. 2011;66:740–9.CrossRef
107.
Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatol (Oxford). 2015;56:247–54.CrossRef
108.
Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007;143:763–7.PubMedCrossRef
109.
Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2022;52:601–7.CrossRef
110.
111.
Argobi Y, Smith GP. Tracking changes in nailfold capillaries during dermatomyositis treatment. J Am Acad Dermatol. 2019;81(1):275–6.PubMedCrossRef
112.
113.
Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett. 2018;195:76–82.PubMedCrossRef
114.
Khanna D, Furst DE, Clements PJ. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord. 2017;2:11–8.PubMedCrossRef
115.
Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology. 2018;57:2106–13.PubMedCrossRef
116.
Thoreau B, Chaigne B, Renaud A, Mouthon L. Treatment of systemic sclerosis. Presse Med. 2021;50: 104088.PubMedCrossRef
117.
Jordan S, Distler JHW, Maurer B. Effects and safety of rituximab in systemic sclerosis: an analysis from the European scleroderma trial and research (EUSTAR) group. Ann Rheum Dis. 2015;74(6):1188–94.PubMedCrossRef
118.
McQueen FM, Solanki K. Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today? Rheumatology. 2015;54:757–67.PubMedCrossRef
119.
Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, et al. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis. 2019;78:979–87.PubMedCrossRef
120.
Daoussis D, Liossis S-NC, Tsamandas AC. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology. 2010;49:271–80.PubMedCrossRef
121.
de Paula DR, Klem FB, Lorencetti PG, et al. Rituximab-induced regression of CREST-related calcinosis. Clin Rheumatol. 2013;32:281–3.PubMedCrossRef
122.
Narváez J, Pirola JP, LLuch J, Juarez P, Nolla JM, Valenzuela A. Effectiveness and safety of rituximab for the treatment of refractory systemic sclerosis associated calcinosis: A case series and systematic review of the literature. Autoimmun Rev. 2019;18:262–9.PubMedCrossRef
123.
124.
Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60:578.PubMedPubMedCentralCrossRef
125.
126.
Campochiaro C, Luca G, Lazzaroni MG. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. Rheumatology (Oxford). 2020;59(12):3731–6.PubMedCrossRef
127.
Ribero S, Sciascia S, Borradori L, Lipsker D. The cutaneous spectrum of lupus erythematosus. Clin Rev Allergy Immunol. 2017;53:291–305.PubMedCrossRef
128.
129.
Biazar C, Sigges J, Patsinakidis N, Ruland V, Amler S, Bonsmann G, et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev. 2013;12:444–54.PubMedCrossRef
130.
Chen KL, Krain RL, Werth VP. Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus. F1000Research. 2019;8:2.CrossRef
131.
Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, et al. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol. BMJ Open. 2019;9: e025687.PubMedPubMedCentralCrossRef
132.
Jones A, Muller P, Dore CJ, Ikeji F, Caverly E, Chowdhury K, et al. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ Open. 2019;9: e032569.PubMedPubMedCentralCrossRef
133.
Lu TY, Ng KP, Cambridge G, Leandro MJ, Edwards JCW, Ehrenstein M, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: the first fifty patients. Arthritis Care Res. 2009;61:482–7.CrossRef
134.
Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus. 2009;18:767–76.PubMedCrossRef
135.
Merrill JT, Neuwelt CM, Wallace DJ. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–33.PubMedPubMedCentralCrossRef
136.
Rovin BH, Furie R, Latinis K. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis assessment with Rituximab study. Arthritis Rheum. 2012;64:1215–26.PubMedCrossRef
137.
Pirone C, Mendoza-Pinto C, Windt DA, Parker B, Sullivan O, M B, et al. Predictive and prognostic factors influencing outcomes of rituximab therapy in systemic lupus erythematosus (SLE): a systematic review. Semin Arthritis Rheum. 2017;47:384–96.PubMedPubMedCentralCrossRef
138.
Alsanafi S, Kovarik C, Mermelstein AL, Werth VP. Rituximab in the treatment of bullous systemic lupus erythematosus. J Clin Rheumatol. 2011;17:142–4.PubMedCrossRef
139.
Lowe CD, Brahe CA, Green B, Lam TK, Meyerle JH. Bullous systemic lupus erythematosus successfully treated with rituximab. Cutis. 2019;103(6):e5-E7.PubMed
140.
Penha MÁ, S LR, Miot HA. Rituximab in the treatment of extensive and refractory subacute cutaneous lupus erythematosus. An Bras Dermatol. 2018;93:467–9.PubMedPubMedCentralCrossRef
141.
Dodds M, Hobday P, Schultz B, Maguiness S. Successful treatment of severe subacute cutaneous lupus erythematosus with rituximab in an adolescent. Pediatr Dermatol. 2108;35(3):189–190.
142.
Kieu V, O’Brien T, Yap L-M. Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab. Australas J Dermatol. 2010;50:202–6.CrossRef
143.
Uthman I, Taher A, Abbas O, Menassa J, Ghosn S. Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case. Dermatology. 2019;216:257–9.CrossRef
144.
Terrier B, Amoura Z, Ravaud P. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2013;62:2458–66.CrossRef
145.
Vital EM, Wittmann M, Edward S. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheumatol. 2022;67:1586–91.CrossRef
146.
Hofmann SC, Leandro MJ, Morris SD, Isenberg DA. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus—report of 17 cases and review of the literature. Lupus. 2013;22:932–9.PubMedPubMedCentralCrossRef
147.
da Quelhas CR, Aguirre-Alastuey ME, Isenberg DA, et al. Assessment of response to B-cell depletion using rituximab in cutaneous lupus erythematosus. JAMA Dermatol. 2018;154:1432–40.CrossRef
148.
Antonelli A, Fallahi P, Elia G. Graves’ disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Pr Res Clin Endocrinol Metab. 2020;34(1): 101388.CrossRef
149.
Fatourechi V, Pajouhi M, Fransway AF. Dermopathy of graves disease (pretibial myxedema. Review of 150 cases. Medicine. 1994;73(1):1–7.PubMedCrossRef
150.
Heyes C, Nolan R, Leahy M, Gebauer K. Treatment-resistant elephantiasic thyroid dermopathy responding to rituximab and plasmapheresis. Australas J Dermatol. 2012;53(1):e1-4.PubMedCrossRef
151.
Genere N, Stan MN. Current and emerging treatment strategies for graves. Orbitopathy Drugs. 2019;79:109–24.PubMedCrossRef
152.
Kotwal A, Turcu AF, Sonawane V. Clinical experience with rituximab and intravenous immunoglobulin for pretibial myxedema: a case series. Thyroid. 2019;29:692–9.PubMedCrossRef
153.
Mitchell AL, Gan EH, Morris M. The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves’ orbitopathy. Clin Endocrinol (Oxf). 2013;79(3):437–42.PubMedCrossRef
154.
Ferreira-Hermosillo A, Casados-V R, Paúl-Gaytán P, Mendoza-Zubieta V. Utility of rituximab treatment for exophthalmos, myxedema, and osteoarthropathy syndrome resistant to corticosteroids due to Graves’ disease: a case report. J Med Case Rep. 2021;12:38–38.CrossRef
155.
Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2022;100:432–41.CrossRef
156.
Salvi M, Vannucchi G, Currò N. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100:422–31.PubMedCrossRef
157.
158.
159.
160.
161.
Goñi Esarte S, Arín Letamendía A, Vila Costas JJ, Jiménez Pérez FJ, Ruiz-Clavijo García D, Carrascosa Gil J, et al. Rituximab as rescue therapy in refractory esophageal lichen planus [in Spanish]. Gastroenterol Hepatol. 2013;36(4):264–7.PubMedCrossRef
162.
Erras S, Mouna Z, Akhdari N, Belaabidia B, Essaadouni L. Rapid and complete resolution of lichen planopilaris in juvenile chronic arthritis treated with rituximab. Eur J Dermatol. 2011;21(1):116–7.PubMedCrossRef
163.
164.
Giudice A, Liborio F, Averta F, Barone S, Fortunato L. Oral lichenoid reaction: an uncommon side effect of rituximab. Case Rep Dent. 2019;2019:3154856.PubMedPubMedCentral
165.
166.
167.
Paul F, Cartron G. Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol. 2019;15:383–9.PubMedCrossRef
168.
Makatsori M, Kiani-Alikhan S, Manson AL. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM. 2014;107:821–8.PubMedCrossRef
169.
170.
171.
Berger JR, Malik V, Lacey S, et al. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event [published correction appears in J Neurovirol. 2018;24(3):332]. J Neurovirol. 2018;24(3):323–31.PubMedPubMedCentralCrossRef
172.
Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 2007;56:2715–8.PubMedCrossRef
173.
Kim MJ, Kim HO, Kim HY, Park YM. Rituximab-induced vasculitis: a case report and review of the medical published work. J Dermatol. 2009;36:284–7.PubMedCrossRef
174.
Karamanakos A, Vergou T, Panopoulos S, Tektonidou MG, Stratigos AJ. Psoriasis as an adverse reaction to biologic agents beyond anti-TNF-α therapy. Eur J Dermatol. 2021;31:307–17.PubMedCrossRef
175.
Vesely NC, Thomas RM, Rudnick E, Longo MI. Scar sarcoidosis following rituximab therapy. Dermatol Ther. 2020;33: e13693.PubMedCrossRef
176.
Sanke S, Mendiratta V, Jassi R, Yadav J, Chander R. Rituximab induced reticulate pigmentation over face in pemphigus vulgaris. Dermatol Ther. 2020;33:e13752. Available at: https://​onlinelibrary-wiley-com.​libproxy.​uams.​edu/​doi/​full/​https://​doi.​org/​10.​1111/​dth.​13752
177.
Mahmoudi H, Nili A, Salehi Farid A, Tavakolpour S, Daneshpazhooh M. Paradoxical worsening of pemphigus after rituximab presenting as figurate bullous eruption. Br J Dermatol. 2021;185:e2. Available at: https://​onlinelibrary-wiley-com.​libproxy.​uams.​edu/​doi/​full/​https://​doi.​org/​10.​1111/​bjd.​20054
178.
Nuño L, Navarro MN, Bonilla G, Franco-Gómez K, Aguado P, Peiteado D, et al. Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. Ann Rheum Dis. 2020;79:1659–61.PubMedCrossRef
179.
Tepasse P, Hafezi W, Lutz M, Kühn J, Wilms C, Wiewrodt R, et al. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol. 2020;190:185–8.PubMedPubMedCentralCrossRef
180.
Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria ATJ, et al. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Ann Rheum Dis. 2021;80: e10.PubMedCrossRef
181.
Schulze-Koops H, Krueger K, Vallbracht I, Hasseli R, Skapenko A. Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Ann Rheum Dis. 2021;80:e67–e67.PubMedCrossRef
182.
Avouac J, Airó P, Carlier N, Matucci-Cerinic M, Allanore Y. Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. Ann Rheum Dis. 2021;80:37.CrossRef
183.
Rodriguez-Pla A, Vikram HR, Khalid V, Wesselius LJ. COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review. Rheumatol Int. 2022;41:1509–14.CrossRef
184.
185.
Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016;75:687–95.PubMedCrossRef
186.
França ILA, Ribeiro ACM, Aikawa NE, Saad CGS, Moraes JCB, Goldstein-Schainberg C, et al. TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology. 2012;51:2091–8.PubMedCrossRef
187.
Arnold J, Winthrop K, Emery P. COVID-19 vaccination and antirheumatic therapy. Rheumatology (Oxford). 2021;60:3496–502.PubMedCrossRef
188.
Shree T, Shankar V, Lohmeyer JJK, Czerwinski DK, Schroers-Martin JG, Rodriguez GM, et al. CD20-targeted therapy ablates de novo antibody response to vaccination but spares preestablished immunity. Blood Cancer Discov. 2022;3:95–102.PubMedPubMedCentralCrossRef
189.
Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D, et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis. 2021;80(10):1345–50.PubMedCrossRef
190.
Agarwal A, Hall R, Banez L, Cardones A. Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: a retrospective analysis. PLoS ONE. 2018;13:2.CrossRef
191.
192.
Rübsam A, Stefaniak R, Worm M, Pleyer U. Rituximab preserves vision in ocular mucous membrane pemphigoid. Expert Opin Biol Ther. 2015;15:927–33.PubMedCrossRef
193.
Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, Caux F, Pascal F, Doan S, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol. 2011;147:843–9.PubMedCrossRef
194.
Heelan K, Walsh S, Shear NH. Treatment of mucous membrane pemphigoid with rituximab. J Am Acad Dermatol. 2013;69:310–1.PubMedCrossRef
195.
Kuye IO, Smith GP. The use of rituximab in the management of refractory dermatomyositis. J Drugs Dermatol. 2017;16:162–6.PubMed
196.
Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2015;44:428–36.PubMedCrossRef
197.
Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert J-M, Decuman S, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69:193–7.PubMedCrossRef
198.
Md Yusof MY, Shaw D, El-Sherbiny YM, Dunn E, Rawstron AC, Emery P, et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis. 2017;76:1829–36.PubMedCrossRef
Metadaten
Titel
Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin
verfasst von
Sophia Ly
Dmitry Nedosekin
Henry K. Wong
Publikationsdatum
11.01.2023
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 2/2023
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-022-00751-7

Weitere Artikel der Ausgabe 2/2023

American Journal of Clinical Dermatology 2/2023 Zur Ausgabe

Systematic Review

Development of Cutaneous T-Cell Lymphoma Following Biologic Treatment: A Systematic Review

Review Article

The Impact of Hyperhidrosis on Quality of Life: A Review of the Literature

Therapy in Practice

Syphilis in Dermatology: Recognition and Management

Review Article

Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors

Review Article

Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management

Original Research Article

Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

16.04.2024 DGIM 2024 Nachrichten

Den Reflex, eine oberflächliche chronische Hautwunde ohne Entzündungszeichen in jedem Fall abzustreichen, sollte man nach einer neuen „Klug-entscheiden“-Empfehlung unterdrücken.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise